Transforming cancer treatment with Protein Phosphatase 2A inhibitors
Investment Snapshot
Ticker: (NASDAQ:LIXT)
Stock Price
Accumulate $5
Winning Scenario
Over $20
Long Term Target*
$40-$50
*Long term is 2+ years
Short Term Target
$8-$10
Editors Note: The shares are oversold, continue trending in the plus $4 range, the wild swings down on the chart are likely shorts hunting stop losses. The Stock is a pressure cooker at these levels.
RISK: The stock is a box checker, low float, Cancer and well-funded, we also believe the short position is underreported. Easily over $20 with just a couple of the upcoming scenarios playing out.
Catalysts:
1B/2 Trial – Ovarian Clear Cell Cancer
1B/2 Trial – Advanced Soft Tissue Sarcoma
1B – Metastatic MSS Colon Cancer
Lixte (NASDAQ:LIXT) is Rewriting the Cancer Treatment Script and has No Rivals in Sight
Lixte Biotechnology (LIXT) holds the world’s only clinical-stage PP2A inhibitor, an exclusive oncology asset protected by long-term patents. With multiple Phase 1b/2 trial results on the horizon, the stock offers compelling catalysts.
- Cancer breakthrough tech: LB-100 helps existing drugs find missed tumors.
- Big Pharma backing: Trials with GSK & Roche at MD Anderson, Northwestern, NKI.
- Huge gap in pricing: $143 probability-weighted value vs. $4.43 today.
- Massive market: Oncology projected to reach $530B by 2032.
- Patient benefit: Reducing toxic doses keeps more patients on treatment.
- Technical Analysis: Simply stated, LIXT has a sweet stock setup.
Readers,
I love writing about promising Biopharmaceutical companies. When they work, they are like a powder keg, ready to ignite and provide early investors with unmatched stock market riches.
LIXTe is positioned to deliver a potential once in a lifetime Cancer protocol platform win for patients and investors. My research and the charts tell me smart investors should buy (NASDAQ:LIXT) up to at least the $8-10 range, soaking up the low hanging shares and let this play out. If we’re right, it could be lifechanging.
(LIXT) is advancing three active Phase 1b/2 trials for LB-100 in combination with established cancer therapies, each partnered with leading organizations. In ovarian clear-cell carcinoma, LB-100 is being tested with GlaxoSmithKline or GSK’s checkpoint inhibitor dostarlimab at MD Anderson and Northwestern University, with interim data expected in Q4 2025. At the Netherlands Cancer Institute, LB-100 is in a trial with Roche’s PD-L1 therapy atezolizumab for MSS colorectal cancer, a patient group that typically does not respond to immunotherapy. In soft-tissue sarcoma, (LIXT) is working with the Spanish Sarcoma Group (GEIS) to combine LB-100 with doxorubicin, with Phase 1b results also anticipated later this year. These collaborations are set to deliver multiple clinical updates in the coming months.
GSK plc (NYSE:GSK) and Roche Holding AG (OTCQX: RHHBY) aren’t just partners, they’re two of the largest cancer drug companies in the world, with multi-billion-dollar oncology portfolios and global market leadership.
Their decision to pair their flagship drugs with LB-100 in combination trials signals that this small cap biotech (LIXT) is on the radar of the biggest players in the industry.
Yes, the biggest Global oncology names are now testing LB-100 with their own cancer therapies. That’s a powerful signal that the market shouldn’t ignore. With multiple collaborations underway, the upcoming news cycle should be nothing short of legendary.
As you’re reading this trading thesis now, pull up the chart and company news, so you can see what’s got Wall Street so excited.
TECHNICALS
The Chart is a Launchpad
LB-100 recently cleared its first safety hurdle, and is now in multiple phase 1b/2 trials with some of the biggest names in medicine.
- LB-100 completed Phase 1 safety studies, with a favorable toxicity profile.
- Advanced into multiple Phase 1b/2 trials in three separate high-value cancer indications.
- Patent protected to 2041+ & backed by 25+ peer-reviewed publications
The stock has been accumulation phase, since the breakthrough news in June and has been hovering near its 52-week high of $5.14; just coiled up for the next catalyst to send this stock soaring!
- Float: Under $5 Million
- July 3 candle: 60M+ shares.
- Resistance: $4.88. Break that and it’s a gunshot to $5.26, then $5.84.
- Support: $4.22, then $3.97 buyers lurking in this range.
Applying a $20 million Market Cap and 4,561,363 shares out, the current price should be around $6.90, which should give everyone confidence to accumulate everything they can get below $8, or higher, as we await upcoming news events.
LIXT’s chart shows major support over $3 and has traded over $4 throughout the August, grinding past $5 several times.
Lixte is poised to run into the teens on positive announcements!
We’re now looking at a risk vs. reward setup where the science cleared the initial safety bar and is squarely in the proof-of-efficacy stage. In the Bayesian model we ran, some best case success probabilities conservative success probabilities produce a probability-weighted value up to $140 per share, versus a current price of $4.43.
“If LB-100 delivers on its proof-of-efficacy stage and moves toward the probability weighted valuation we modeled, the math is staggering.”
“At under $5 today versus a modeled $140+ per share target, you’re looking at gains north of 3,000% from current levels essentially more than a 31× return possible on the receipt of positive results on upcoming trials!”
And that’s using conservative trial success probabilities and standard licensing multiples, not blue-sky scenarios. In biotech terms, that’s the kind of asymmetric setup where a single clinical win can reprice the entire company overnight.
- Market cap: Under $20 million, float under $5 million shares.
- Multiple catalysts: Expected in next 12–18 months.
- Probability-weighted valuation model: $415M total value up to ($143/share).
- Comparable Cancer Stocks: Several surged 300–1,000+% on positive trial results.
An Explosive Sector Produces Explosive Gains, Over and Over Again.
How many of these did you miss?
Ticker:
SMMT
Company Focus:
Bispecific antibody therapies for NSCLC (ivonescimab)
Low Price:
$8.90
High Price:
$35+
Key Catalysts:
Positive Phase III lung cancer data; +576% in 2024
Ticker:
CRBP
Company Focus:
Antibody–drug conjugates for solid tumors (CRB-701)
Low Price:
$4.64
High Price:
$60+
Key Catalysts:
Strong Phase I oncology data; one of top 2024 biotech gainers
Ticker:
JANX
Company Focus:
Cancer immunotherapies (TRACTr platform)
Low Price:
$8
High Price:
$70+
Key Catalysts:
Major clinical advancements in prostate/colorectal cancer
Ticker:
MNPR
Company Focus:
Radiopharmaceuticals & therapies (MNPR-101)
Low Price:
$0.30
High Price:
$50+
Key Catalysts:
+1,089% on radiopharma developments for advanced cancers
Additional High-Performance Drug Developers
Not strictly cancer-focused but show similar explosive dynamics:
Ticker:
VKTX
Company Focus:
Metabolic drugs (VK2809 for liver disease/obesity)
Low Price:
$8
High Price:
$99+
Key Catalysts:
Phase II obesity drug data; multi-bagger run
Ticker:
DRUG
Company Focus:
Neurological drugs (psychedelic-inspired)
Low Price:
$1
High Price:
$100+
Key Catalysts:
+1,857% on Phase II seizure disorder trials
“Get the Valuation Model ……. Why up to $143/share Isn’t Hype”
LB-100 Could Be High Grade Biotech Artillery!
Lixte’s revolutionary cancer breakthrough. LB-100, helps existing drugs find otherwise undetected tumors and make them glow like Vegas to the immune system. When it finds these tumors, it shuts down the cancer cell’s ability to repair itself and also disrupts RNA splicing, while enhancing checkpoint inhibitors.
“The Single Most Asymmetric Cancer Trade on Wall Street Right Now— Featuring a Revolutionary Drug, a $500B Market, and a Chart Screaming for a Short-Squeeze Explosion”
LB-100 is a first-in-class PP2A inhibitor. In plain English that means it flips the switch inside cancer cells that normally helps them survive chemo, dodge immunotherapy, and fix damage.
When LB-100 is active:
- Tumors can’t repair themselves
- They become visible to the immune system (game-changer for PD-1 combos)
- It makes other treatments hit harder and smarter
This drug is being tested in some of the most aggressive, treatment-resistant cancers:
- Ovarian Clear-Cell Carcinoma (almost nothing works here)
- Microsatellite-Stable Colorectal Cancer (85% of CRC patients can’t use immunotherapy; LB-100 may flip the script)
- Soft Tissue Sarcoma (rare, brutal, and in desperate need of options)
If that wasn’t enough? Preclinical studies are exploring LB-100 as a cancer preventive in patients with RAS-mutant cell populations.
That’s right; a therapeutic that might stop cancer before it begins.
However, here’s the real kicker: LIXTE is the only company on Earth with a clinical-stage PP2A inhibitor.
No competition. First mover. NIH patents. Pharma salivating.
LIXTE Owns:
Patent Portfolio Overview
Composition & Use Patents (USPTO & International)
- LB‑100 as a therapeutic molecule is protected by U.S. Patents 7,998,957, 8,227,473, 8,822,461, 10,023,587, and 10,532,050, plus international counterparts, covering pharmaceutical compositions and uses in treating a range of cancers including breast, colon, lung, ovarian, and leukemia.
- Expiration dates range from 2028 to 2034, depending on the specific patent and any available term extensions (SEC).
Combination Therapy Patents (Pending & Notice of Allowance)
- LB‑100 used in combination with checkpoint inhibitors and other immunotherapies is covered by pending patent applications. LIXTE received a Notice of Allowance (USTPO application 16/467,721, Oxabicycloheptanes for Modulation of Immune Response), which is expected to issue soon.
- These combination therapy patents are co-owned with the U.S. government via NIH instruments, specifically under exclusive license from NINDS and NCI. Projected expiration is around 2037 (Stock Titan).
Extended Protection: Specialized Indications & Partner Programs
- Additional pending patents cover LB‑100 combinations with small-cell lung cancer agents like carboplatin, etoposide, and atezolizumab, with projected 2041 expiration.
- Further claims, including use of LB‑100 with investigational molecules and specific disease contexts, like myelodysplastic syndromes, extend the portfolio potentially into 2035–2043 (SEC).
- Multiple issued U.S. patents on composition and use of LB‑100 (good through 2034).
- Co-licensed combo patents with the NIH for immunotherapy pairings—expires 2037+.
- Pending patents for combo treatments (atezolizumab, doxorubicin, etc.) extend out to 2041.
That’s 15+ years of exclusivity on a first-in-class compound.
Obesity and Cancer are today’s Two Greatest Health Challenges
Obesity and cancer are now internationally recognized as the two largest threats to human health and healthcare systems. Obesity is a primary driver of heart disease, diabetes, and metabolic disorders and a known risk factor for at least 13 different types of cancer. Meanwhile, cancer itself remains the second-leading cause of death worldwide, with hundreds of billions spent annually on treatment. Together, they account for an enormous share of healthcare costs, lost productivity, and reduced quality of life.
The investment implications are clear: companies that develop safe, effective therapies in these categories are tackling urgent unmet markets worth hundreds of billions of dollars. That’s why GLP-1 weight-loss drug developers like Novo Nordisk and Eli Lilly have seen such explosive valuation growth, and why cancer drug innovators with promising clinical data often experience dramatic stock price re-ratings. LB-100, which is partnered with GSK and Roche and positioned to enhance the effectiveness of existing cancer therapies, is the kind of high-impact, high-visibility space where a single successful trial can translate into outsized returns.
One of the biggest hidden risks in oncology is treatment discontinuation due to side effects.
Studies show that up to 59% of patients stop cancer treatment when faced with even moderate toxicities. Among elderly patients on chemotherapy, 42% discontinue altogether and 55% experience dose delays or interruptions because of adverse reactions. Even in broader patient populations, roughly 10% reduce their dose and another 9.7% interrupt treatment entirely within the first few months. These figures represent millions of patients worldwide losing critical time for therapies to work. LB-100’s ability to sensitize tumors to partner drugs like chemotherapy or immunotherapy may allow oncologists to use lower doses of those agents, potentially reducing toxicity, helping patients stay on treatment longer, and ultimately improving outcomes. This not only addresses a major unmet clinical need but also enhances the commercial potential of any drug paired with LB-100.
LB‑100 has been under scientific evaluation for nearly a decade, with its first human safety and tolerability study published in Clinical Cancer Research in 2017, marking the beginning of its translation from bench to bedside. Since then, research into LB‑100 has grown significantly: the compound’s mechanism and preclinical efficacy are detailed in over 25 peer-reviewed publications, spanning studies on chemotherapy synergy, immunotherapy enhancement, glioblastoma models, and neoantigen generation (LIXTE).
A peer-reviewed study in EMBO Reports demonstrated, in mid-2024, that LB‑100 disrupts RNA splicing to activate neoantigen presentation, further solidifying its immunotherapy application.
Taken together, these data sets underscore a sustained and expanding research base that validates LB-100’s potential in oncology across multiple mechanistic pathways.
- 8 key peer-reviewed papers — formal publications in major journals (e.g., Clinical Cancer Research, Nature Communications, Journal of Neuro-Oncology, Cancers, EMBO Reports) detailing LB-100’s safety, mechanism, and preclinical/clinical results.
- More than 28 total scientific papers — including conference abstracts, mechanistic studies, and collaborator-authored reports outside of Lixte, covering applications from glioblastoma and colorectal cancer to triple-negative breast cancer and CAR-T enhancement.
LB‑100 is a PP2A inhibitor and that’s a molecular hitman for cancer. It makes tumors wave a white flag by:
- Screwing up their internal wiring (RNA disruption),
- Exposing them to the immune system (it’s like putting a neon sign over the bad guy),
- And making other drugs like chemo and checkpoint inhibitors way more effective.
This thing turns cold tumors into hot targets. It’s the cancer equivalent of handing a sniper rifle to your immune system.
Biotech’s big, right?
Try $530 billion by 2032, but here’s the kicker—LB‑100 isn’t trying to fight for one little slice of that.
It’s a power-up drug. It doesn’t need to be the hero.
It makes the heroes stronger.
If this thing proves out in ovarian, colorectal, sarcoma, you’re talking dozens of indications, hundreds of licensing opportunities, big pharma bending the knee to cut a deal.
Cancer therapy market?
$231 BILLION in 2025, heading to $530 BILLION+ by 2032.
And LIXTE’s not going after some rare gene mutation, we’re talking:
- Ovarian clear-cell carcinoma (super resistant, nothing works)
- Microsatellite-stable colorectal cancer (85% of CRC cases)
- Soft tissue sarcoma
- Pre-cancerous RAS-mutant prevention (yes, prevention!)
If LB‑100 works it becomes a platform drug. Used in dozens of indications, with hundreds of potential licensing deals. Think Adjuvant X for cancer.
Major Upcoming Catalysts
H2 2025 – Buckle up
Date
Event
Why it matters
Q3
MSI‑Low Colorectal (Phase 1b/2) early efficacy
85% of CRC patients don’t respond to immunotherapy—if LB‑100 fixes that? Lights out.
Q3-Q4
Ovarian Clear Cell interim readout
GSK’s dostarlimab + LB‑100—if this combo pops, expect a headline partner deal.
Q4
Soft Tissue Sarcoma Phase 2 update
With doxorubicin—clean survival data here gives them a fast-path label.
Q4
RAS-Mutant Pre-cancer Prevention Study
Prevention = new frontier. If they show animal data wiping out pre-cancer cells? Think “cancer vaccine 2.0.”
Top 10 Reasons to Own LIXTE
- First-in-Class Drug: LB-100 is the only PP2A inhibitor in clinical trials, a novel chemo and immunotherapy enhancer.
- Massive Market Opportunity: Targeting cancers inside a $530 billion global oncology market.
- Zero Competition: No clinical-stage competitors. LIXTE has first-mover advantage and deep IP.
- Tiny Float: Just 2.3 million shares tradeable, with explosive upside potential on volume surges.
- High Borrow Cost: 400%+ borrow fee makes this nearly unshortable, a setup for squeeze dynamics.
- Recent Institutional Activity: $5M private placement closed in July, funding trials and launching a 60M volume spike.
- Loaded Clinical Pipeline: Three Phase 1b/2 trials across high-value cancer targets; prevention study in motion.
- Massive Asymmetry: Trading at a $12M market cap with upside potential into the billions.
- No Analyst Coverage Yet: The market is sleeping and you can get in before institutions start assigning price targets.
- Upcoming Catalysts in H2 2025: Trial data, partnerships, and possible fast-track headlines all approaching within months.
Key Peer-Reviewed Publications on LB-100
- Chung V et al., 2017 “Safety, Tolerability, and Preliminary Activity of LB‑100…”, Clinical Cancer Research First-in-human Phase I trial showing safety and early activity in refractory solid tumors (PubMed)
- **Hong CS et al., 2015** “LB‑100, a small molecule inhibitor of PP2A…”, Cancer Biology & Therapy Review of preclinical chemo- and radio-sensitization effects of LB‑100 (PubMed)
- Ho WS et al., 2018 “Pharmacologic inhibition of protein phosphatase‑2A achieves durable immune-mediated antitumor activity when combined with PD‑1 blockade”, Nature Communications Synergy of LB‑100 with anti-PD‑1 in murine cancer models (LIXTE, Nature)
- Yen YT et al., 2021 “Protein phosphatase 2A inactivation induces microsatellite instability, neoantigen production and immune response”, Nature Communications Demonstrates LB‑100’s ability to trigger neoantigen production and immune sensitization in colorectal cancer models (Nature)
- **Maggio D et al., 2020** “Inhibition of protein phosphatase‑2A with LB‑100 enhances antitumor immunity against glioblastoma”, Journal of Neuro‑Oncology Preclinical study showing immune enhancement in GBM models (LIXTE)
- Cui J et al., 2020 “Inhibition of PP2A with LB‑100 Enhances Efficacy of CAR‑T Cell Therapy Against Glioblastoma”, Cancers LB‑100 enhances CAR-T cytotoxicity in glioblastoma xenograft models (MDPI)
- **Review in Cancers, 2021** “PP2A biology and LB‑100 as a therapeutic strategy for CNS tumors”, Cancers Comprehensive review of LB‑100’s role in CNS tumor models (MDPI, MDPI)
- Additional mechanistic studies (2019–2021) Several collaborators have published on LB‑100 inducing immune sensitivity via mechanisms like spliceosome interference and checkpoint augmentation (PMC, Oncotarget)
There’s a real ecosystem around LB-100 beyond the company.
8–10 prominent labs/centers are involved across clinical trials and independent preclinical work. Here’s a tight “top 10” with what each is doing:
- MD Anderson Cancer Center (Houston, TX) — Ovarian clear-cell combo trial with GSK’s dostarlimab.
- Northwestern University (Chicago, IL) — Co-site on the ovarian clear-cell LB-100 + dostarlimab trial.
- Netherlands Cancer Institute (NKI, Amsterdam) — MSS/MSS-low colorectal trial with Roche’s atezolizumab; also preclinical combo work.
- Oncode Institute (NL) — Collaborative preclinical synergy studies with NKI.
- City of Hope (Duarte, CA) — Led the first-in-human Phase 1 safety/tolerability study (Chung et al., Clin Cancer Res 2017).
- Wayne State University (Detroit, MI) — Independent TNBC work showing LB-100 sensitizes to paclitaxel/cisplatin and inhibits growth in resistant lines.
- GEIS – Spanish Sarcoma Group (Spain) — Clinical collaboration on LB-100 + doxorubicin in soft-tissue sarcoma.
- NIH – National Cancer Institute (NCI) — Lists LB-100–based trials; NIH labs are tied to IP/licensing and combination-therapy research frameworks. (gov)
- NIH – NINDS — Included in LIXTE’s referenced NIH licensing around immune-combo IP
- Academic consortium behind EMBO Reports (2024) — External teams demonstrated LB-100 rewires spliceosome phosphorylation to create neoantigens in colon cancer cells (mechanism validation).
If LB-100 ultimately proves effective as an adjunct to a wide range of cancer treatments from chemotherapy and immunotherapy to targeted agents and CAR-T it could be considered a once-in-a-generation breakthrough.
Unlike a single-use drug, LB-100 has the potential to function as a platform technology, enhancing the power of existing therapies while allowing for lower, less toxic doses. That combination could keep more patients on treatment longer, addressing the reality that up to 59% of cancer patients discontinue therapy due to side effects. With patents extending into the 2040s, partnerships with global leaders like GSK and Roche, and applicability across multiple cancer types, LB-100 is positioned not just to change treatment protocols, but to impact millions of lives worldwide, while opening the door to multi-billion-dollar licensing and royalty streams in a projected $530-billion oncology market
With a market cap of around $20 million
LB-100 is trading at a fraction of its modeled probability-weighted value; a gap that could quickly flip once data hits. In Q4 2025, results are expected from three separate trials, two of them partnered with GSK and Roche, the planet’s biggest names in oncology. These companies don’t commit their flagship cancer drugs to outside trials without compelling science, potential for meaningful results, and an eye on commercial impact. For investors, this is a rare alignment of deep undervaluation, imminent catalysts, and validation from industry leaders; the kind of once-in-a-lifetime setup where a single positive readout could reprice the stock overnight.
In our Bayesian probability weighted model, even the most conservative assumptions show significant upside for LB-100. In the low scenario, where only one current indication succeeds with modest revenue potential, the valuation comes out to about $19.65 per share more than 4×$4.43. In the mid scenario, with two indications succeeding and moderate revenues, the model points to roughly $69.88 per share. And in the high scenario, where all three active trials succeed with stronger peak revenue estimates, the probability weighted value reaches approximately $177.45 per share. The range illustrates the asymmetry of the opportunity even limited success could produce substantial gains, while full success could mean a 40× return from current levels.
The BOTTOM Line
Everything you’ve just read points to a company with a unique technology, validation from two of the biggest cancer drug makers in the world, support from leading research organizations, multiple imminent trial readouts, and a market valuation that doesn’t yet reflect its potential. There’s far more to uncover, so don’t stop here. Go to LIXTE’s website, read their press releases, watch the available videos, and dig into the independent due diligence. When you see the science, the partnerships, and the timing lined up the way they are now, I believe you’ll see exactly what I see; a rare, high conviction opportunity that may not come around again.
We’ve had a strong run of winners this past year and I’m convinced LIXT has all the hallmarks of another one, unique science, heavyweight partners, and multiple near-term catalysts.
That said, biotech is a high-volatility sector and even the most promising stories can hit unexpected setbacks. Stay tuned to the market, monitor company news closely, and always protect yourself against potential negative catalysts these stocks are known for.
Life changing gains are truly possible here, but they come with risk so limit your exposure to what you can afford and manage it with discipline.
Good Luck,
Editor
Do yourself a favor and sign up to receive breaking news Alerts so you don’t miss out on updates about Ten Holdings.
DISCLOSURE: 24/7 Market News Inc. (247), owns and operates 247marketnews.com is a third-party publisher and news release service provider which disseminates corporate news electronically through multiple online media platforms. 247 is NOT an affiliate with any of the companies mentioned in our reports. 247 is a news distribution service and is not registered with FINRA or any other professional licensing service. 247 is not an analyst, broker dealer or advisor, and holds no such licenses. 247 may NOT offer to buy, sell, or hold any security. 247 Venture Beats, and Breakfast bits and any other corporate profiles will NEVER be a solicitation or recommendation of any kind, of any security mentioned. The materials in all our releases are intended to be for informational purposes only and should never be considered research or due diligence on any company mentioned. All readers are encouraged to perform standard due diligence by reading the company’s filings at SEC.gov. Readers should consult their broker or licensed professional before investing in any company. All materials in this release are based on publicly available statements made by the companies. 247 is not liable for any investment decisions made by any readers or subscribers. Any investment could result in you losing all your money from investing in any stock. 247’s editor owns no shares of Lixtie Biotechnology Holdings Inc., LIXT and will not trade in the stock. Publisher has been paid for ongoing investor outreach, and news coverage by Microcap strategy on behalf of the company of up to twenty-five thousand dollars a week for the next three months. 24/7 will also be using financial marketing tools to engage with the investment community online. Editors are paid to put a best-case scenario profile out to the investing public. This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and 247 undertakes no obligation to update such statements. Or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and 247 undertakes no obligation to update such statements. Or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and 247 undertakes no obligation to update such statements. Including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and 247 undertakes no obligation to update such statements. Including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and 247 undertakes no obligation to update such statements. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and 247 undertakes no obligation to update such statements. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and 247 undertakes no obligation to update such statements.
All information, opinions, analyses, technical analysis, trading price targets, and support and resistance interpretations presented in this publication represent the author’s personal views and are fully protected under the First Amendment of the United States Constitution. The content provided herein is intended solely as editorial opinion, general market commentary, or educational material, and should never be construed as financial or investment advice. This publication does not constitute a solicitation or recommendation to buy or sell securities, commodities, or any other financial instruments. Readers are strongly advised to conduct their own independent research or seek professional advice before making any investment decisions. For additional information regarding First Amendment protections for financial newsletters and commentary, please refer to Lowe v. SEC, 472 U.S. 181 (1985): https://supreme.justia.com/cases/federal/us/472/181/
Copyright © 2025 24/7 MarketNews